The NK cancer drug provider has filed to go public in an offering which would enable GC and its GC Labcell subsidiary to exit.

Artiva Biotherapeutics, a US-based immunotherapy developer backed by pharmaceutical group GC, has filed for a $100m initial public offering on the Nasdaq Global Market.

Founded in 2019, Artiva is working on cell-based cancer therapies. Its lead drug candidate, AB-101, helps the body produce natural killer (NK) cells that destroy cancer and tumour cells.

The proceeds of the offering will go toward the research and development of AB-101, as well as AB-201 and AB-202, which are chimeric antigen receptor NK…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn